BRCA1 Expression and Outcome in Patients With

EGFR GOAL study Gefitinib Lung cancer Olaparib

Journal

JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 18 06 2020
revised: 30 09 2020
accepted: 17 10 2020
entrez: 30 9 2021
pubmed: 1 10 2021
medline: 1 10 2021
Statut: epublish

Résumé

DNA repair capacity, as exemplified by We evaluated the impact of Overall, as what happened in the GOAL study, no statistically significant difference was observed in median progression-free survival (PFS) between the two treatment arms, for the 91 patients of the present study ( High

Identifiants

pubmed: 34589994
doi: 10.1016/j.jtocrr.2020.100113
pii: S2666-3643(20)30159-4
pmc: PMC8474244
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100113

Informations de copyright

© 2020 The Authors.

Références

Science. 2007 May 25;316(5828):1194-8
pubmed: 17525340
Clin Cancer Res. 2011 Mar 1;17(5):1160-8
pubmed: 21233402
EBioMedicine. 2018 Mar;29:112-127
pubmed: 29433983
J Thorac Oncol. 2013 Mar;8(3):295-300
pubmed: 23407556
EBioMedicine. 2019 Jan;39:207-214
pubmed: 30473379
Nature. 2018 Nov;563(7729):131-136
pubmed: 30356214
Cancer Discov. 2012 Dec;2(12):1134-49
pubmed: 22993403
Cell. 2009 Jul 10;138(1):51-62
pubmed: 19576624
Oncogene. 2016 Sep 1;35(35):4569-79
pubmed: 26898760
Cell. 2010 Apr 16;141(2):243-54
pubmed: 20362325
Cancer Discov. 2014 Dec;4(12):1430-47
pubmed: 25252691
Cancer Res. 1998 Mar 15;58(6):1120-3
pubmed: 9515792
Cancer Res. 2003 Oct 1;63(19):6221-8
pubmed: 14559807
J Thorac Oncol. 2019 Feb;14(2):304-310
pubmed: 30472259
Clin Cancer Res. 2017 Oct 15;23(20):6239-6253
pubmed: 28698200
N Engl J Med. 2009 Sep 3;361(10):958-67
pubmed: 19692684
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2201-6
pubmed: 20133863
Lung Cancer. 2020 Dec;150:62-69
pubmed: 33070053
Mol Cell. 2015 Oct 1;60(1):163-76
pubmed: 26344098
Nat Genet. 2012 Jul 01;44(8):852-60
pubmed: 22751098
Lancet Oncol. 2013 Jul;14(8):777-86
pubmed: 23782814

Auteurs

Niki Karachaliou (N)

Pangaea Oncology, Quirón-Dexeus University Hospital, Barcelona, Spain.
Instituto Oncológico Dr Rosell (IOR), University Hospital Sagrat Cor, Quirón Salud Group, Barcelona, Spain.

Oscar Arrieta (O)

Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.

Ana Giménez-Capitán (A)

Pangaea Oncology, Quirón-Dexeus University Hospital, Barcelona, Spain.

Erika Aldeguer (E)

Pangaea Oncology, Quirón-Dexeus University Hospital, Barcelona, Spain.

Ana Drozdowskyj (A)

Molecular and Cellular Oncology Laboratory, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Spain.

Imane Chaib (I)

Molecular and Cellular Oncology Laboratory, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Spain.

Noemí Reguart (N)

Medical Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Rosario Garcia-Campelo (R)

Medical Oncology Department, University Hospital A Coruña (XXIAC-SERGAS), A Coruña, Spain.

Jing-Hua Chen (JH)

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
Medical Oncology Department, Guangzhou Twelfth People's Hospital, Guangzhou, People's Republic of China.

Miguel Angel Molina-Vila (MA)

Pangaea Oncology, Quirón-Dexeus University Hospital, Barcelona, Spain.

Rafael Rosell (R)

Pangaea Oncology, Quirón-Dexeus University Hospital, Barcelona, Spain.
Molecular and Cellular Oncology Laboratory, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Spain.

Classifications MeSH